Bharat Biotech’s Covid-19 vaccine phase-3 trials cross half-way mark of 13,000 volunteers

Bharat Biotech has announced the successful recruitment of 13,000 volunteers, and continued its progress towards achieving its goal of 26,000 participants for phase-3 clinical trial across multiple sites in the country of India’s first Make in India vaccine candidate, Covaxin, against the coronavirus disease (Covid-19).

The phase-3 human clinical trials of Covaxin began mid-November, targeting 26,000 volunteers across the country at multiple sites.

However, Bharat Biotech’s application for emergency use authorisation (EUA) clearance for their Covid-19 vaccine candidate is still pending with the national drugs regulator, Drugs Controller General of India, for want of adequate safety and efficacy data.

Prime Minister Narendra Modi visited the Bharat Biotech facility in Hyderabad on November 28 and interacted with the scientists. He congratulated them for the progress they had made in the vaccine trials.

The Prime Minister’s visit was followed by the visit of as many as 64 ambassadors and high commissioners from several nations to learn more about the work in the Bharat Biotech facility to produce a safe and efficacious vaccine against Covid-19.